IOVA IOVANCE BIOTHERAPEUTICS, INC.
FY2025 10-K
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed its fiscal year 2025 10-K annual report with the SEC on Feb 24, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Commercial-stage biopharma pioneering individualized tumor infiltrating lymphocyte (TIL) cell therapies for solid tumor cancers
- • New/regulatory: Amtagvi approved in U.S. and Canada, pending UK/Australia 2026 approvals, withdrawn and resubmitting EU MAA in 2026
Management Discussion & Analysis
- • Revenue $263.5M, up 61% YoY; Amtagvi $220.0M (up $116.5M), Proleukin $43.5M (down $17.0M)
- • Cost of sales $173.2M, up 86%; R&D $300.3M, up 9%; SG&A flat at $152.3M; total expenses $666.9M, up 19%
Risk Factors
- • Cybersecurity risk from internal systems and CROs, requiring increased resources to counter sophisticated threats
- • Dependency on IT infrastructure vulnerable to security breaches impacting business operations
Get deeper insights on IOVANCE BIOTHERAPEUTICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.